Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|2|E52-E54

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.2, 2018-02, pp. : E52-E54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3612-3621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 179-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 204-207

John Wiley & Sons Inc

Access to resources Recommend Favorite

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite